The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer

BackgroundAnaphase-promoting complex subunit 1 (ANAPC1) is a regulator of cellular mitosis and an important factor in tumorigenesis. To date, a comprehensive assessment of the potential role, biological behaviours, and clinical significance of ANAPC1 in colorectal cancer (CRC) is still lacking.Materials and methodsThis study integrated 2329 mRNA expression data, single-cell RNA sequencing (scRNA-seq), and internal immunohistochemistry of 416 tissue samples to comprehensively evaluate the abnormal expression pattern of ANAPC1 in CRC. It also incorporated evidence from immune infiltration analysis, functional enrichment analysis, and weighted gene co-expression network analysis to explore the biological behaviour of ANAPC1 in CRC. In addition, in vitro cell biology experiments such as real-time polymerase chain reaction (RT-PCR), western blot (WB), cholecystokinin 8 (CCK-8), wound healing, cell cycle, and apoptosis assays were conducted to verify the potential effect of ANAPC1 on CRC cells.ResultsANAPC1 mRNA was significantly overexpressed in CRC tissue (SMD = 2.07, 95% CI 1.59-2.55, <i>P</i> < .05) and malignant epithelial cells (<i>P</i> < .05). Validation at the protein level similarly confirmed the overexpression of ANAPC1 in CRC tissue (<i>P</i> < .05). ANAPC1 in CRC may play a role in abnormal ribosome biogenesis, DNA replication, ATP-dependent activity acting on DNA, nuclear division, chromosome segregation, and other pathways. In vitro experiments demonstrated that HCT-116 cells with ANAPC1 knockdown had reduced proliferation and migration abilities, increased cell apoptosis rate, and altered cell cycle distribution. In addition, CRC patients with low ANAPC1 expression were more likely to benefit from treatment with immune checkpoint inhibitors. ANAPC1 was significantly downregulated in malignant epithelial cells of CRC treated with PD-1 inhibitors (<i>P</i> < .05).ConclusionANAPC1 may have a positive impact on the development of CRC by being involved in pathways related to DNA replication, chromosome segregation, and ribosomes.

Authors

Institutions

Publication Details

Journal
Cancer Control
Published
2025-04-14
DOI
https://doi.org/10.1177/10732748251330059
Citations
1
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer

Yuzhen Chen, Da-Tong Zeng, Rong‐Quan He, Qiuyu Wei et al.
1 citations
Cancer Control
Ferroptosis and cancer prognosis
1.52
article

The Potential Biological Roles and Clinical Significance of Anaphase-Promoting Complex Subunit 1 in Colorectal Cancer

Yuzhen Chen, Da-Tong Zeng, Rong‐Quan He, Qiuyu Wei, Jiaying Wen, Gang Chen, Zhi‐Guang Huang, Yi Chen, Dongming Li, Yu-Xing Tang, Hui Li, Yan-Ting Zhan, Yu-Lu Tang
article en
1 citations

Abstract

BackgroundAnaphase-promoting complex subunit 1 (ANAPC1) is a regulator of cellular mitosis and an important factor in tumorigenesis. To date, a comprehensive assessment of the potential role, biological behaviours, and clinical significance of ANAPC1 in colorectal cancer (CRC) is still lacking.Materials and methodsThis study integrated 2329 mRNA expression data, single-cell RNA sequencing (scRNA-seq), and internal immunohistochemistry of 416 tissue samples to comprehensively evaluate the abnormal expression pattern of ANAPC1 in CRC. It also incorporated evidence from immune infiltration analysis, functional enrichment analysis, and weighted gene co-expression network analysis to explore the biological behaviour of ANAPC1 in CRC. In addition, in vitro cell biology experiments such as real-time polymerase chain reaction (RT-PCR), western blot (WB), cholecystokinin 8 (CCK-8), wound healing, cell cycle, and apoptosis assays were conducted to verify the potential effect of ANAPC1 on CRC cells.ResultsANAPC1 mRNA was significantly overexpressed in CRC tissue (SMD = 2.07, 95% CI 1.59-2.55, <i>P</i> < .05) and malignant epithelial cells (<i>P</i> < .05). Validation at the protein level similarly confirmed the overexpression of ANAPC1 in CRC tissue (<i>P</i> < .05). ANAPC1 in CRC may play a role in abnormal ribosome biogenesis, DNA replication, ATP-dependent activity acting on DNA, nuclear division, chromosome segregation, and other pathways. In vitro experiments demonstrated that HCT-116 cells with ANAPC1 knockdown had reduced proliferation and migration abilities, increased cell apoptosis rate, and altered cell cycle distribution. In addition, CRC patients with low ANAPC1 expression were more likely to benefit from treatment with immune checkpoint inhibitors. ANAPC1 was significantly downregulated in malignant epithelial cells of CRC treated with PD-1 inhibitors (<i>P</i> < .05).ConclusionANAPC1 may have a positive impact on the development of CRC by being involved in pathways related to DNA replication, chromosome segregation, and ribosomes.

Cancer ControlVol. 32
Guangxi Medical University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Yulin Orthopedics Hospital of Chinese and Western Medicine (CN)
Youth Science Foundation of Guangxi Medical University
Good health and well-being
Openalex Percentile: Top 20%
Ferroptosis and cancer prognosis
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.